Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Crossref DOI link: https://doi.org/10.1007/s00280-017-3287-8
Published Online: 2017-04-19
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Quach, Hang
White, Darrell
Spencer, Andrew
Ho, P. Joy
Bhutani, Divaya
White, Mike
Inamdar, Sandeep
Morris, Chris
Ou, Ying
Gyger, Martin
Funding for this research was provided by:
Amgen Inc.
License valid from 2017-04-19